NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE (lamivudine; nevirapine; zidovudine) by Hetero is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination oral tablet containing lamivudine, nevirapine, and zidovudine for HIV-1 treatment in adults and pediatric patients weighing at least 6 kg. The combination pairs two nucleoside reverse transcriptase inhibitors (lamivudine, zidovudine) with a non-nucleoside reverse transcriptase inhibitor (nevirapine) to suppress viral replication. This triple-therapy approach represents a foundational antiretroviral regimen designed for resource-limited settings and patients initiating HIV treatment.
Pre-Launch
Pre-launch stage signals active development, market entry planning, and commercial team expansion for positioning in competitive HIV-1 combination therapy space.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.